Finoriq research workspace
BridgeBio Oncology Therapeutics, Inc. (BBOT) SEC Filings & Filing Highlights
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the. Review BBOT SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
- Company
- BridgeBio Oncology Therapeutics, Inc. (BBOT)
- Ticker
- BBOT
- Market Cap
- $673.7M
- Latest Price
- $8.41
- Industry
- Biotech & Pharma
BridgeBio Oncology Therapeutics, Inc. (BBOT) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for BridgeBio Oncology Therapeutics, Inc. (BBOT).
| Event | Form | Date |
|---|---|---|
| The proposals set forth below were submitted to the stockholders at the Annual Meeting held on...The proposals set forth below were submitted to the stockholders at the Annual Meeting held on June 16, 2026, with each such proposal descr... | 8-K5.07 | 2026-06-22 |
| On June 16, 2026, Michelle Doig notified BridgeBio Oncology Therapeutics, Inc. (the “Company”),...On June 16, 2026, Michelle Doig notified BridgeBio Oncology Therapeutics, Inc. (the “Company”), of her resignation as a member of the Board... | 8-K5.02 | 2026-06-22 |
| BBOT Reports First Quarter 2026 Financial Results and Update on Corporate ProgressBBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress | 8-K2.02 | 2026-05-12 |
| As previously reported in a Current Report on Form 8-K filed by BridgeBio Oncology Therapeutics...As previously reported in a Current Report on Form 8-K filed by BridgeBio Oncology Therapeutics, Inc. (the “Company”) with the Securities a... | 8-K5.02 | 2026-04-29 |
| BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmel...BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kum... | 8-K7.01 | 2026-04-23 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.